These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1116 related items for PubMed ID: 21680574

  • 1. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype.
    Ricardo S, Vieira AF, Gerhard R, Leitão D, Pinto R, Cameselle-Teijeiro JF, Milanezi F, Schmitt F, Paredes J.
    J Clin Pathol; 2011 Nov; 64(11):937-46. PubMed ID: 21680574
    [Abstract] [Full Text] [Related]

  • 2. Cancer stem cells markers CD44, CD24 and ALDH1 in breast cancer special histological types.
    de Beça FF, Caetano P, Gerhard R, Alvarenga CA, Gomes M, Paredes J, Schmitt F.
    J Clin Pathol; 2013 Mar; 66(3):187-91. PubMed ID: 23112116
    [Abstract] [Full Text] [Related]

  • 3. Immunohistochemical detection of breast cancer stem cells in hormone receptor-positive breast cancer and their role in response to endocrine therapy and clinical outcome.
    Hashimoto K, Shimizu C, Tsuda H, Saji S, Osaki A, Shigekawa T, Aogi K.
    Oncology; 2012 Mar; 82(3):168-74. PubMed ID: 22433454
    [Abstract] [Full Text] [Related]

  • 4. Characteristic genes in luminal subtype breast tumors with CD44+CD24-/low gene expression signature.
    Tsunoda Y, Sakamoto M, Sawada T, Sasaki A, Yamamoto G, Tachikawa T.
    Oncology; 2011 Mar; 81(5-6):336-44. PubMed ID: 22237177
    [Abstract] [Full Text] [Related]

  • 5. Cancer stem cell markers are associated with adverse biomarker profiles and molecular subtypes of breast cancer.
    Tsang JY, Huang YH, Luo MH, Ni YB, Chan SK, Lui PC, Yu AM, Tan PH, Tse GM.
    Breast Cancer Res Treat; 2012 Nov; 136(2):407-17. PubMed ID: 23053657
    [Abstract] [Full Text] [Related]

  • 6. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers.
    Tanei T, Morimoto K, Shimazu K, Kim SJ, Tanji Y, Taguchi T, Tamaki Y, Noguchi S.
    Clin Cancer Res; 2009 Jun 15; 15(12):4234-41. PubMed ID: 19509181
    [Abstract] [Full Text] [Related]

  • 7. Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer.
    Rennstam K, McMichael N, Berglund P, Honeth G, Hegardt C, Rydén L, Luts L, Bendahl PO, Hedenfalk I.
    Breast Cancer Res Treat; 2010 Jul 15; 122(2):315-24. PubMed ID: 19795205
    [Abstract] [Full Text] [Related]

  • 8. The clinicopathological and prognostic significance of CD24, CD44, CD133, ALDH1 expressions in invasive ductal carcinoma of the breast: CD44/CD24 expression in breast cancer.
    Kapucuoğlu N, Bozkurt KK, Başpınar Ş, Koçer M, Eroğlu HE, Akdeniz R, Akçil M.
    Pathol Res Pract; 2015 Oct 15; 211(10):740-7. PubMed ID: 26298632
    [Abstract] [Full Text] [Related]

  • 9. CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome.
    Idowu MO, Kmieciak M, Dumur C, Burton RS, Grimes MM, Powers CN, Manjili MH.
    Hum Pathol; 2012 Mar 15; 43(3):364-73. PubMed ID: 21835433
    [Abstract] [Full Text] [Related]

  • 10. Prognostic significance of CD24 and claudin-7 immunoexpression in ductal invasive breast cancer.
    Bernardi MA, Logullo AF, Pasini FS, Nonogaki S, Blumke C, Soares FA, Brentani MM.
    Oncol Rep; 2012 Jan 15; 27(1):28-38. PubMed ID: 21956537
    [Abstract] [Full Text] [Related]

  • 11. CD44(+)/CD24(-) cells are transit progenitors and do not determine the molecular subtypes and clinical parameters in breast carcinomas.
    Lü X, Xu K, Lü H, Yin Y, Ma C, Liu Y, Li H, Suo Z.
    Ultrastruct Pathol; 2011 Apr 15; 35(2):72-8. PubMed ID: 21299347
    [Abstract] [Full Text] [Related]

  • 12. Distribution of CD44/CD24 positive cells in ductal invasive carcinoma of breast of different grade and molecular subtype.
    Gudadze M, Kankava K, Mariamidze A, Mosidze T, Burkadze G.
    Georgian Med News; 2013 Sep 15; (222):50-7. PubMed ID: 24099815
    [Abstract] [Full Text] [Related]

  • 13. Features of CD44+/CD24-low phenotypic cell distribution in relation to predictive markers and molecular subtypes of invasive ductal carcinoma of the breast.
    Gudadze M, Kankava Q, Mariamidze A, Burkadze G.
    Georgian Med News; 2014 Mar 15; (228):81-7. PubMed ID: 24743129
    [Abstract] [Full Text] [Related]

  • 14. СD44+/CD24- markers of cancer stem cells in patients with breast cancer of different molecular subtypes.
    Chekhun SV, Zadvorny TV, Tymovska YO, Anikusko MF, Novak OE, Polishchuk LZ.
    Exp Oncol; 2015 Mar 15; 37(1):58-63. PubMed ID: 25804234
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Clinicopathologic correlation of cancer stem cell markers CD44, CD24, VEGF and HIF-1α in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.
    Wang Z, Shi Q, Wang Z, Gu Y, Shen Y, Sun M, Deng M, Zhang H, Fang J, Zhang S, Xie F.
    Pathol Res Pract; 2011 Aug 15; 207(8):505-13. PubMed ID: 21802218
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Impact of CD44+CD24- cells on non-sentinel axillary lymph node metastases in sentinel node-positive breast cancer.
    Nogi H, Suzuki M, Kamio M, Kato K, Kawase K, Toriumi Y, Takeyama H, Fukushima H, Morikawa T, Uchida K.
    Oncol Rep; 2011 Apr 15; 25(4):1109-15. PubMed ID: 21308353
    [Abstract] [Full Text] [Related]

  • 20. The clinicopathologic and prognostic significance of CD44+/CD24(-/low) and CD44-/CD24+ tumor cells in invasive breast carcinomas.
    Mylona E, Giannopoulou I, Fasomytakis E, Nomikos A, Magkou C, Bakarakos P, Nakopoulou L.
    Hum Pathol; 2008 Jul 15; 39(7):1096-102. PubMed ID: 18495204
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 56.